Encorafenib
| Use attributes for filter ! | |
| Molar mass | 540. 011 g/mol |
|---|---|
| Trade name | Braftovi |
| Drug class | Antineoplastic Agents |
| Other names | LGX818 |
| ATC code | L01XE46 (WHO) |
| License data | US |
| DailyMed | |
| ChemSpider ID | 28536139 |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951339 |
About Encorafenib
Encorafenib is a drug for the treatment of certain melanomas. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers. The substance was being developed by Novartis and then by Array BioPharma.